AMPed Up about Partnerships

Partnerships Open New Windows for Treatment Development

03.06.14 | By Stephanie Fischer

Since the Accelerating Medicines Partnership (AMP) was announced last month, there’s been robust discussion throughout the scientific community and the general public about the goals of this unique partnership between the National Institutes of Health (NIH), several non-profit disease foundations, 10 biopharmaceutical companies and PhRMA, and how they will be implemented to ultimately benefit patients. 

Earlier this week, Dr. Bill Chin, Executive Vice President of Scientific and Regulatory Affairs at PhRMA, shared his thoughts in the Friends of Cancer Research Engaging Innovation blog on the importance of public-private partnerships such as AMP to advance innovation and tackle broad, far-reaching public health issues.  The hope is that through this type of collaborative effort, the scientific community will be able to increase collectively the odds of success in finding new diagnostics and therapies, while reducing the time and cost associated with their development. 

In a show that aired on Sunday, BioCenturyTV hosted a panel discussion on AMP featuring Dr. Chin, Dr. Francis Collins, Director of NIH; David Wholley, Director of the Biomarkers Consortium at the Foundation for the National Institutes of Health (FNIH); and Sandra Raymond, President and CEO of the Lupus Foundation of America.  The conversation highlighted the recognition by the stakeholders convened through AMP that bold, new efforts are needed to accelerate medical progress and that no single group – government, academia, industry, patient advocates– could succeed in every aspect on their own. 

Additional companies and researchers will have an opportunity to participate in AMP research and benefit from the findings.  Dr. Collins highlighted that AMP will support competitive research so there will be requests for applications (RFAs) and requests for discovery (RFDs) through the FNIH.  And the partners have agreed to make AMP data and analyses publicly accessible to the broad biomedical community. 

During the panel discussion, Sandra Raymond noted that pharmaceutical companies have been pursuing therapies for lupus even though the disease targets are not currently well-understood, which has meant few approved therapies for lupus patients.  It is envisioned that through the AMP partnership, basic science research will be conducted more quickly than if researchers or companies worked alone, providing the biomedical research community with a better understanding of these diseases, which can facilitate the development of new therapies. 

As Dr. Chin wrote for Engaging Innovation, “PhRMA is committed to working across the scientific ecosystem and finding ways to put these partnerships into practice, in a way that will result in meaningful advances in treatment discovery.”


BioCentury 03.02.14 - [1] The Problem


Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context